• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >Novel therapeutic targets in the treatment of IBD
【24h】

Novel therapeutic targets in the treatment of IBD

机译：在治疗IBD的新疗法靶标

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Advances in mucosal immunology have revealed a broad set of new therapeutic targets to resolve inflammation and symptoms in patients with inflammatory bowel diseases (IBD). Objective: Despite the enormous success of anti-TNF therapies in IBD, these treatments have limited efficacy, and there continues to be concerns regarding their toxicity. Thus, a considerable unmet need exists for better treatment of these disorders. Methods: New therapeutic targets include other pro-inflammatory cytokines such as IL-6, IL-12, IL-17 or IFN-γ, and others. In addition, molecules directing trafficking of inflammatory cells such as integrin α4β7 or intracellular adhesion molecule 1 (ICAM-1) might be attractive candidates as anti-inflammatory targets. Targeting intestine-specific homing by blocking chemokine receptors such as CCR9 might provide a new avenue for treatment in the future. Conclusion: All these and many other different therapies are currently being investigated in IBD, the challenge will be to develop more effective therapies than those currently available.
机译：背景：粘膜免疫学的进展揭示了广泛的新治疗靶标，可以解决炎症性肠病（IBD）患者中的炎症和症状。目的：尽管IBD的抗TNF疗法巨大成功，但这些治疗有限有限，并且仍然存在对其毒性的担忧。因此，存在相当大的未掩盖，以便更好地治疗这些疾病。方法：新的治疗靶标包括其他促炎细胞因子，如IL-6，IL-12，IL-17或IFN-γ等。此外，指导抗炎症细胞如整联蛋白α4β7或细胞内粘附分子1（ICAM-1）的分子可能是有吸引力的候选者作为抗炎靶标。通过阻断CCR9等趋化因子受体来靶向肠特异性归巢，可以在将来提供新的治疗途径。结论：目前在IBD中调查了所有这些和许多其他不同的疗法，挑战将是发展比目前可用的疗法更有效的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号